• Anti-Inflammatory, Anti-Angiogenic Stent Suppresses TISR

  2026-05-14

  Zhao et al. developed an airway stent that integrates anti-inflammatory and anti-angiogenic strategies to effectively suppress tracheal in-stent restenosis in a rabbit model. By combining anlotinib hydrochloride and silver nanoparticles, the study provides mechanistic and transcriptomic evidence for multi-faceted suppression of fibrosis, angiogenesis, and infection, suggesting a promising translational direction for airway intervention.

• Hesperadin: Precision Aurora B Kinase Inhibitor for Mitosis

  2026-05-13

  Hesperadin is a potent Aurora B kinase inhibitor that disrupts mitotic progression by targeting the kinase’s ATP-binding pocket. It is highly effective in inhibiting chromosome alignment and segregation in cell cycle research, with precise IC50 values validated in vitro and in cellular assays. APExBIO supplies this compound for advanced studies on mitotic regulation and cancer.

• Amitriptyline HCl (B2231): Technical Guidance for Lab Use

  2026-05-13

  Amitriptyline HCl (SKU B2231) provides researchers with a high-purity, well-characterized agent for rigorous study of neurotransmitter receptor modulation, specifically targeting serotonin, norepinephrine, and related pathways. This compound is optimal for neuropharmacology, cell-based, and signal transduction assays, but should not be used outside the validated applications described in the product specification.

• Erastin: Precision Ferroptosis Inducer for Cancer Research

  2026-05-12

  Erastin is the gold-standard ferroptosis inducer, enabling selective, iron-dependent cell death assays in RAS/BRAF-mutant tumor models. This article delivers a bench-to-publication blueprint for robust ferroptosis workflows, protocol optimization, and troubleshooting, grounded in the latest redox signaling research.

• Machine Learning Discovers Novel Senolytics: Implications fo

  2026-05-12

  This study presents a machine learning-driven approach to identify senolytic compounds, significantly reducing the cost and scope of early-stage drug discovery. The validated discovery of potent senolytics such as ginkgetin, periplocin, and oleandrin in diverse human cell models suggests practical routes for targeting senescent cells in cancer and age-related disease contexts.

• ROS-Scavenging Smart Hydrogel Accelerates Diabetic Wound Hea

  2026-05-11

  This study introduces a thermosensitive hydrogel integrating MnO2 nanozymes and TGF-β1 to address diabetic wound healing impeded by oxidative stress. The hydrogel’s synergistic ROS scavenging, immune modulation, and smart release properties yielded rapid wound closure and tissue regeneration in diabetic models.

• Cy7 NHS Ester: Technical Guide for Near-Infrared Protein Lab

  2026-05-11

  Cy7 NHS ester enables efficient, hydrophilic labeling of proteins and peptides for near-infrared fluorescent imaging, particularly in contexts where water solubility, reduced quenching, and gentle conjugation are required. It is not suitable for workflows demanding long-term solution storage or exclusive use with organic solvents.

• Hybridization Reshapes Pluripotency Networks in Xenopus laev

  2026-05-10

  This study demonstrates that ancient hybridization in Xenopus laevis led to divergent regulation of its two subgenomes, rewiring the pluripotency transcriptional network. The work highlights how maternal factors activate each subgenome asymmetrically, with implications for developmental biology and evolutionary genomics.

• Metoprolol: Selective Beta1-Adrenoceptor Antagonist for Rese

  2026-05-09

  Metoprolol is a selective beta1-adrenoceptor antagonist widely employed in cardiovascular disease research. Its mechanism, stability, and validated anti-inflammatory and anti-tumor activities make it a benchmark tool for biomedical studies (source: https://www.apexbt.com/metoprolol-ba2737.html).

• Maraviroc (UK-427857): Transforming CCR5 Antagonism in RA &

  2026-05-08

  This thought-leadership article explores Maraviroc’s (UK-427857) mechanistic and translational value as a selective CCR5 antagonist. Building on breakthrough findings in HIV-1 entry inhibition and new insights from extracellular vesicle-mediated pathogenesis in rheumatoid arthritis, we dissect the molecule’s dual-domain potential. The discussion integrates evidence from recent literature, highlights best practices for translational workflows, and provides strategic guidance for researchers navigating the rapidly evolving landscape of CCR5-targeted therapy.

• Iptacopan (LNP023): Applied Protocols for Complement Researc

  2026-05-08

  Iptacopan (LNP023) sets a new benchmark for selective, reversible inhibition of the alternative complement pathway in both cellular and animal models. This guide translates rigorous clinical and preclinical data into actionable protocols and troubleshooting strategies for complement activation research.

• Amikacin (BAY416651): Mechanism, Resistance, and Research Ut

  2026-05-07

  Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic renowned for its resistance to most aminoglycoside-modifying enzymes and its pivotal role in antibiotic resistance research. Studies in carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae models demonstrate its utility in understanding multidrug resistance. APExBIO supplies research-grade Amikacin for these advanced applications.

• PPT (Propyl Pyrazole Triol): Precision Tool for ERα-Driven B

  2026-05-07

  Explore how PPT (Propyl Pyrazole Triol), a potent ERα agonist, enables precise dissection of estrogen receptor signaling and biomarker discovery, with unique insights from recent ceRNA network research. Discover advanced assay protocols, translational relevance, and workflow strategies.

• FLOT1–FOSL2–EphA2 Axis Regulates Microglial Polarization in

  2026-05-06

  This study reveals that the interaction between FLOT1 and FOSL2 promotes EphA2 transcription, activating microglial pro-inflammatory polarization via the p38/MAPK pathway in Alzheimer’s disease. These findings clarify how neuroinflammation is regulated in AD, identify new therapeutic targets, and inform the development of more precise neurotoxicity models.

• THZ1: Precision Covalent CDK7 Inhibition in Cancer Cell Mode

  2026-05-06

  Explore how THZ1, a potent covalent CDK7 inhibitor, refines cancer research through its unique mechanism and resistance profile. This article offers new insight into protocol design and translational potential for transcription regulation inhibitor strategies.

16495 records 1/1100 page Next 12345 下5页 Last page